Protocol summary
-
Study aim
-
Bioequivalence Study of Azithromycin 500 mg manufactured by Sanamed company versus originator brand (Zythromax) manufactured by Pfizer company
-
Design
-
Bioequivalence study, crossover, single-blinded, 24 healthy volunteers. Simple randomization was used for randomization
-
Settings and conduct
-
The study is a single-blinded, cross-over and fasting, and on two series of healthy volunteers. The study will be done in two periods (72h). The interval between these two periods is two weeks. In the first round of the study, the candidates divide into two groups and the first group receives a test tablet and the second group receives a brand tablet. Blood samples are collected immediately before and after drug administration by volunteers. Then, drug extraction is done and samples are ready for analysis. Sampling is performed in Radin laboratory in Tabriz.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria: General Health (Liver, Heart, and Kidney), Body Mass Index (18-28), Informed consent, Age (18-55 years old) Exclusion criteria: Smoking, History of cardiovascular disease, History of liver and kidney disease, Alcohol and drug addiction, History of allergy to Azithromycin
-
Intervention groups
-
Intervention group 1: Zythromax 500mg tablet as a reference Intervention group 2: Azithromycin 500 mg manufactured by Sanamed as a test
-
Main outcome variables
-
Maximum drug concentration, Time to reach maximum drug concentration, Half-life of drug
General information
-
Reason for update
-
Changing sampling date and place
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20200623047902N13
Registration date:
2022-01-22, 1400/11/02
Registration timing:
prospective
Last update:
2024-07-16, 1403/04/26
Update count:
1
-
Registration date
-
2022-01-22, 1400/11/02
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2022-07-21, 1401/04/30
-
Expected recruitment end date
-
2023-03-20, 1401/12/29
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Bioequivalence Study of Azithromycin 500 mg tablet manufactured by Sanamed company versus the originator brand in healthy volunteers
-
Public title
-
Bioequivalence study of Azithromycin 500 mg tablet
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28)
Informed consent
Age (18-55 years old)
Exclusion criteria:
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcohol and drug addiction
History of allergy to Azithromycin
-
Age
-
From 18 years old to 55 years old
-
Gender
-
Both
-
Phase
-
Bioequivalence
-
Groups that have been masked
-
-
Sample size
-
Target sample size:
24
More than 1 sample in each individual
Number of samples in each individual:
18
Blood sample
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
People in the mentioned age group are invited to participate through the advertisement. People are then checked for health and healthy volunteers are identified. Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball and poured into a container and mixed. The balls are then removed randomly from the container. The first 12 no.s are considered as (first sequence: Sanamed's medicine ) and the second 12 no.s are considered as (second sequence: originator brand recipient). The volunteers don't have any information about taking the test drug or brand drug
-
Blinding (investigator's opinion)
-
Single blinded
-
Blinding description
-
This study is a single-blinded clinical trial (volunteers). Sanamed's Azithromycin and Originator brand's tablets are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form
-
Placebo
-
Not used
-
Assignment
-
Crossover
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2022-01-12, 1400/10/22
-
Ethics committee reference number
-
IR.TBZMED.REC.1400.1047
Health conditions studied
1
-
Description of health condition studied
-
This study is performed on healthy volunteers.
-
ICD-10 code
-
-
ICD-10 code description
-
Primary outcomes
1
-
Description
-
Drug plasma concentration
-
Timepoint
-
0; 0.5; 1; 1.5; 2; 2.5; 3; 3.5; 4; 4.5, 5, 6; 8; 10; 12, 24, 48 and 72h after drug administration
-
Method of measurement
-
Liquid Chromatography Mass-Mass
Secondary outcomes
1
-
Description
-
Time to reach maximum plasma concentration
-
Timepoint
-
After intervention
-
Method of measurement
-
Time to reach the maximum drug concentration in plasma is recorded.
2
-
Description
-
Extent of absorption
-
Timepoint
-
After intervention
-
Method of measurement
-
Calculation of area under curve of concentration -time
Intervention groups
1
-
Description
-
Intervention group: single dose, one oral tablet 500mg (Zithromax) manufactured by Pfizer, as a reference product
-
Category
-
Treatment - Drugs
2
-
Description
-
Intervention group: Single dose, one oral Azithromycin 500mg tablet manufactured by Sanamed company as test product
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Sanamed pharma company
-
Proportion provided by this source
-
100
-
Public or private sector
-
Private
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Industry
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
No - There is not a plan to make this available
-
Justification/reason for indecision/not sharing IPD
-
These data are as secure between researcher and related industries.
-
Study Protocol
-
No - There is not a plan to make this available
-
Statistical Analysis Plan
-
No - There is not a plan to make this available
-
Informed Consent Form
-
No - There is not a plan to make this available
-
Clinical Study Report
-
No - There is not a plan to make this available
-
Analytic Code
-
No - There is not a plan to make this available
-
Data Dictionary
-
No - There is not a plan to make this available